Literature DB >> 17786539

Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells.

Nikolaos A Dallas1, Fan Fan, Michael J Gray, George Van Buren, Sherry J Lim, Ling Xia, Lee M Ellis.   

Abstract

Vascular endothelial growth factor (VEGF) has been shown to be the major mediator of physiologic and pathologic angiogenesis. VEGF was initially thought to be an endothelial cell specific ligand, but recently, VEGF has been shown to mediate tumor cell function via activation of receptors on tumor cells themselves. Here, we review the expression patterns and binding profiles of the VEGF receptors and their ligands on gastrointestinal tumor cells. Furthermore, we describe the current knowledge in regards to the function of these receptors on tumor cells. Elucidating the function of VEGF receptors on tumor cells should help us to better understand the potential mechanisms of action of anti-VEGF therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786539     DOI: 10.1007/s10555-007-9070-2

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  24 in total

Review 1.  Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

Authors:  S A Kono; L E Heasley; R C Doebele; D R Camidge
Journal:  Curr Cancer Drug Targets       Date:  2012-02       Impact factor: 3.428

Review 2.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

3.  Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment.

Authors:  Yoon-Jin Lee; Daniel L Karl; Ugwuji N Maduekwe; Courtney Rothrock; Sandra Ryeom; Patricia A D'Amore; Sam S Yoon
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

4.  Functional significance of VEGFR-2 on ovarian cancer cells.

Authors:  Whitney A Spannuth; Alpa M Nick; Nicholas B Jennings; Guillermo N Armaiz-Pena; Lingegowda S Mangala; Christopher G Danes; Yvonne G Lin; William M Merritt; Premal H Thaker; Aparna A Kamat; Liz Y Han; James R Tonra; Robert L Coleman; Lee M Ellis; Anil K Sood
Journal:  Int J Cancer       Date:  2009-03-01       Impact factor: 7.396

5.  Rationale for combining biotherapy in the treatment of advanced colon cancer.

Authors:  Deirdre J Cohen; Howard S Hochster
Journal:  Gastrointest Cancer Res       Date:  2008-05

Review 6.  Tumor angiogenesis.

Authors:  Robert S Kerbel
Journal:  N Engl J Med       Date:  2008-05-08       Impact factor: 91.245

7.  TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types.

Authors:  Amit Chaudhary; Mary Beth Hilton; Steven Seaman; Diana C Haines; Susan Stevenson; Peter K Lemotte; William R Tschantz; Xiaoyan M Zhang; Saurabh Saha; Tony Fleming; Brad St Croix
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

Review 8.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Trends Pharmacol Sci       Date:  2012-03-06       Impact factor: 14.819

9.  Direct and Precise Measurement of Bevacizumab Levels in Human Plasma Based on Controlled Methionine Oxidation and Multiple Reaction Monitoring.

Authors:  Vanessa P Gaspar; Sahar Ibrahim; Constance A Sobsey; Vincent R Richard; Alan Spatz; René P Zahedi; Christoph H Borchers
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-13

10.  Selective blockade of tumor angiogenesis.

Authors:  Amit Chaudhary; Brad St Croix
Journal:  Cell Cycle       Date:  2012-06-15       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.